HVIVO Secures £6m Influenza Human Challenge Trial Contract
Why It Matters
The contract fast‑tracks development of stronger flu antivirals, giving hVIVO a competitive edge while promising quicker, more effective prophylactic options for seasonal influenza.
Key Takeaways
- •hVIVO signs £6m contract for influenza challenge trial.
- •Study split into safety cohort then immediate efficacy testing.
- •Human challenge design bypasses seasonal delays, accelerates data collection.
- •Prophylactic antiviral efficacy hard to test in traditional field trials.
- •Growing funding shift from vaccines to antiviral development drives demand.
Summary
hVIVO announced a £6 million contract to run a human challenge study testing a prophylactic antiviral against influenza. The agreement, detailed by Chief Scientific Officer Andrew Catchpole, marks a significant step for the company’s antiviral pipeline.
The trial is divided into two phases: an initial safety cohort to confirm dosing, followed immediately by an efficacy cohort. Because challenge studies are not tied to the flu season, data can be generated year‑round, eliminating the months‑long lag typical of field trials.
Catchpole highlighted that controlled timing of drug administration and viral exposure cuts through the noise of natural infection studies. He also noted hVIVO’s recent investment in potent influenza challenge strains, which increase disease signal and improve efficacy detection. The shift in funding from vaccine development toward antivirals has boosted demand for such specialized testing.
Accelerating proof‑of‑concept data positions hVIVO as a go‑to partner for pharma, potentially shortening the path to market for more effective flu antivirals and reshaping seasonal influenza treatment strategies.
Comments
Want to join the conversation?
Loading comments...